Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and other alternative treatments in Germany:a pharmacovigilance impact study by Hedenmalm, Karin et al.
                                                              
University of Dundee
Effect of withdrawal of fusafungine from the market on prescribing of antibiotics and
other alternative treatments in Germany
Hedenmalm, Karin; Kurz, Xavier; Morales, Daniel
Published in:
European Journal of Clinical Pharmacology
DOI:
10.1007/s00228-019-02650-z
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Hedenmalm, K., Kurz, X., & Morales, D. (2019). Effect of withdrawal of fusafungine from the market on
prescribing of antibiotics and other alternative treatments in Germany: a pharmacovigilance impact study.
European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-019-02650-z
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
Effect of withdrawal of fusafungine from the market on prescribing
of antibiotics and other alternative treatments
in Germany: a pharmacovigilance impact study
Karin Hedenmalm1,2 & Xavier Kurz3 & Daniel Morales3
Received: 3 October 2018 /Accepted: 15 February 2019
# The Author(s) 2019
Abstract
Purpose Knowledge on unintended consequences of product withdrawals is limited. Fusafungine, indicated for treatment of
upper respiratory airways disease (URAD), was withdrawn in the EU on May 28, 2016. Given concerns about possible
substitution with antibiotics, this study aimed to assess the impact of the withdrawal of fusafungine on prescribing of antibiotics
and other treatments.
Methods The study was conducted using data from general practitioner (GP) and ear, nose and throat (ENT) practices in IMS®
Disease Analyzer Germany. The quarterly prevalence of fusafungine prescribing was analysed for consultations involving the
most common URAD between May 29, 2013 and May 28, 2017 in regular fusafungine-prescribing practices. Trends in the
quarterly prevalence of antibiotics (AB), other nasal or throat preparations (N&T) and tyrothricin were analyzed. Practices with
no fusafungine prescribing during the study served as controls. Changes in prescribing trend were evaluated using interrupted
time series regression analysis.
Results In fusafungine-prescribing practices, withdrawal of fusafungine was associated with an immediate increase in prescrib-
ing of other N&Ts among patients consulting for URAD (+ 6.4%, 95% CI 2.3–10.5% in GP practices and + 9.0%, 95% CI 5.5–
12.5% in ENT practices). There was no increase in antibiotic prescribing. In ENT practices; a small transient increase in
tyrothricin prescribing occurred. No changes were seen in non-fusafungine-prescribing practices.
Conclusions Withdrawal of fusafungine was not associated with increased prescribing of antibiotics but was associated with
increased prescribing of other N&Ts. The unintended impact of substitution to other treatments should be considered routinely
when products are withdrawn or restricted in other ways.
Keywords Fusafungine . Upper respiratory airways disease . Antibiotics . Alternative prescribing
Introduction
Fusafungine is an antimicrobial and anti-inflammatory agent
administered via inhalation into the nostrils or orally. It was
authorised in 19 EuropeanUnion (EU)member states for local
antibacterial and anti-inflammatory treatment of upper respi-
ratory airways disease (URAD), including sinusitis, rhinitis,
rhinopharyngitis, angina, laryngitis and tracheitis [1].
Fusafungine consists of a mixture of enniatins [2] and has
been widely used over the past 50 years [1]. Its first authori-
sation in the EU was in 1963. Fusafungine has multiple mech-
anisms of action, including downregulation of the expression
of intercellular adhesion molecule-1 (ICAM-1) and inhibition
of production of proinflammatory cytokines [3]. In September
2015, an EU-wide assessment of the benefit-risk of
fusafungine was initiated due to an increase in the reporting
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rate of serious allergic reactions [4], estimated at a rate of 0.17
cases per 100,000 canisters [1]. In February 2016, the
European Medicines Agency (EMA) Pharmacovigilance
Risk Assessment Committee (PRAC) recommended that
fusafungine should be withdrawn from the EU market, and
this recommendation was implemented with immediate effect
on 28 May 2016 [5, 6]. In addition to the risk of serious
allergic reactions, contributing factors to the withdrawal deci-
sion included the lack of evidence around efficacy/
effectiveness and the inability to exclude the risk of antimi-
crobial resistance [1, 6].
Medicinal products are removed from the market due to
unfavorable benefit-risk profiles. However, these decisions
might lead to substitutions to alternative medicines that are
not always necessary, safer or more effective. The aim of this
study was to estimate the impact of the market withdrawal of
fusafungine in Germany on potential alternative treatments
including antibiotics, locally acting antimicrobials and other
nasal or throat preparations for the management of URAD.
Methods
Data source
Germany was selected for the study due to a high rate of
prescriptions for fusafungine [7], whereas in some other EU
countries (e.g. France and the United Kingdom) fusafungine
was not available on the market. The study used data from the
IMS® Disease Analyzer Germany, version June 2017. IMS®
Disease Analyzer Germany contains anonymised medical re-
cords from a representative panel of general practitioners
(GPs), specialists in internal medicine and other specialist
physicians in computerized practices throughout Germany
since 1992 [8]. Primary care data fromGermany contains data
on diagnoses, prescriptions, and risk factors such as smoking
or obesity, referrals and sick notes and test results. In
Germany, patients are not required to register with a GP to
be referred to a specialist physician.
Study design
A time series study design was used to measure the
impact of fusafungine withdrawal among patients seek-
ing consultation for URAD. The study observation pe-
riod was from 29 May 2013 to 28 May 2017. Practices
included in the study were required to have continuous
data delivery between May 2013 and June 2017. The
study included data from GPs and ear, nose and throat
(ENT) specialists capturing 98.6% of all fusafungine
prescriptions.
Indication for treatment
Consultations for the most commonly occurring URAD con-
ditions were defined by screening and ranking clinical diag-
noses recorded on the same day as fusafungine in order of
frequency. The three most common diagnoses that were se-
lected and included for GP practices were acute pharyngitis
(ICD code J02.9), acute upper airways infection (ICD code
J06.9) and acute laryngitis (ICD code J04.0), and for ENT
practices, they were acute laryngitis (ICD code J04.0), acute
pharyngitis (ICD code J02.9) and acute laryngopharyngitis
(ICD code J06.0).
Fusafungine-prescribing practices
Trends in prescribing were compared between regular
fusafungine-prescribing practices and non-fusafungine-
prescribing practices. Regular fusafungine-prescribing prac-
tices were defined as practices having at least 0.5% of all
patients prescribed fusafungine, and at least 5% of patients
consulting for URAD, in each year for 3 years prior to the
withdrawal of fusafungine. GP and ENT practices with no
fusafungine prescribing in the same period were then selected
as a control group.
Exposures
Four types of exposure were analyzed: prescriptions for
fusafungine-containing products, prescriptions for system-
ic antibiotics, prescriptions for other locally acting antimi-
crobials besides fusafungine, i.e. tyrothricin-containing
products and prescriptions for other nasal or throat prep-
arations (N&Ts). Fusafungine- and tyrothricin-containing
products were identified by substance name belonging to
the EphMRA ATC code R01A4 (nasal anti-infectives
without corticosteroids) and R02A0 (throat preparations)
respectively. Other N&Ts were identified by EphMRA
ATC codes: R01A topical nasal preparations, R01B sys-
temic nasal preparations and R02A throat preparations,
excluding products containing fusafungine or tyrothricin.
Systemic antibiotics were identified by the following
EphMRA ATC codes: J01A tetracyclines and combina-
tions, J01B chloramphenicol and combinations, J01C
broad-spectrum penicillins, J01D cephalosporins, J01E
trimethoprim and similar preparations, J01F macrolides
and similar types, J01G fluoroquinolones, J01H plain me-
dium and narrow spectrum penicillins and penicillin/
streptomycin combinations, J01K aminoglycosides, J01L
carbenicillin and similar types, J01P other beta-lactam an-
tibacterials excluding penicillins and cephalosporins and
J01X other antibacterials.
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Analysis
Among patients consulting for URAD, trends in the following
treatments were examined over the study period using quar-
terly time intervals: (1) treatment with systemic antibiotics, (2)
treatment with fusafungine, (3) treatment with tyrothricin, (4)
treatment with other N&T, and (5) no treatment. The treat-
ments were defined as mutually exclusive groups. Quarterly
time intervals were defined from 29 May to 28 August, 29
August to 28 November, 29 November to 28 February and 29
February/1 March to 28 May for each year. Interrupted time
series regression analysis was chosen to statistically evaluate
the effect of the withdrawal [9]. Using linear regression anal-
ysis, the immediate impact of the withdrawal and any change
in subsequent trends in prescribing was compared between the
12 pre-intervention quarters and the 4 post-intervention quar-
ters [10]. Autocorrelation was evaluated using the Durbin
Watson test [11–13]. Analysis was conducted using SAS
Enterprise Guide version 7.13. All analyses were performed
by the authors based on IMS® Disease Analyzer Germany.
Results
A total of 31 GP (3.0%) and 17 ENT (15.5%) regular
fusafungine-prescribing practices were identified, within
which 4644 GP patients (3.8%) and 7527 ENT patients
(3.4%) were prescribed fusafungine during the study period.
Of these patients, 64.2% of GP patients and 64.6% of ENT
patients had a concomitant diagnosis of URAD identified. In
GP practices, the most common URAD diagnosis was upper
airways infection, followed by acute pharyngitis, acute laryn-
gitis and acute laryngopharyngitis. In ENT practices, the most
common URADs were acute pharyngitis, acute laryngitis,
acute laryngopharyngitis and upper airways infection. The
distribution of diagnoses was similar in regular fusafungine-
prescribing practices compared to non-fusafungine-
prescribing practices (Supplementary material, Table A1).
Prescribing trends in URAD
Regular fusafungine-prescribing GP and ENT practices
Trends in the quarterly prevalence of prescribing of each treat-
ment for URAD are shown in Fig. 1. for both regular
fusafungine-prescribing practices and non-fusafungine-
prescribing control practices. Among regular fusafungine-
prescribing GP practices, the quarterly prevalence of
fusafungine prescribing immediately fell in the quarter follow-
ing the date of withdrawal (immediate change − 7.8%, 95%CI
− 11.8 to − 3.7%) (Table 1). Among regular fusafungine-
prescribing ENT practices, the quarterly prevalence of
fusafungine prescribing also immediately fell in the quarter
following the date of withdrawal (immediate change −
13.7%, 95% CI − 17.3 to − 10.1%).
Among regular fusafungine-prescribing GP practices, the
quarterly prevalence of other N&T prescribing immediately
rose in the quarter following the date of withdrawal (immedi-
ate change 6.4%, 95% CI 2.3 to 10.5%) with no significant
change in trend compared to the pre-intervention trend.
Among regular fusafungine-prescribing ENT practices, the
quarterly prevalence of other N&T prescribing also immedi-
ately rose in the quarter following the date of withdrawal
(immediate change 9.0%, 95% CI 5.5 to 12.5%) with no sig-
nificant change in trend compared to the pre-intervention
trend.
Fusafungine withdrawal was associated with a small sig-
nificant immediate increase in tyrothricin prescribing in regu-
lar fusafungine-prescribing ENT practices only (immediate
change 1.7%, 95%CI 1.3 to 2.2%), with a significant decrease
in trend compared to the pre-intervention trend (− 0.3%, 95%
CI − 0.5 to − 0.2%). In both GP and ENT regular fusafungine-
prescribing practices, there was no significant immediate in-
crease or change in trend in systemic antibiotic prescribing
associated with fusafungine withdrawal.
Non-fusafungine-prescribing control practices
Fusafungine withdrawal was not associated with any signifi-
cant changes in prescribing of systemic antibiotics, tyrothricin
or other N&T in non-fusafungine-prescribing GP or ENTcon-
trol practices.
Discussion
Electronic health records provide an important means to study
the impact of medicines regulatory interventions on prescrib-
ing behaviour. Our study found that in regular fusafungine
prescribing GP and ENT practices in Germany, the withdraw-
al of fusafungine was associated with an immediate change in
health care professional behaviour with increased prescribing
of other N&T products for URAD. In this regard, there was no
significant change in the proportion of untreated patients, an
effect similarly noted in other interventions resulting in chang-
ing antibacterial guideline recommendations [14].
Importantly, we observed no statistically significant increase
in prescribing of systemic antibiotics and only a small tempo-
rary increase in prescribing of tyrothrocin-containing products
from ENT practices, which is reassuring in terms of the risk of
antibiotic resistance and other antibiotic-related adverse drug
reactions that may have occurred. In this regard, a decreased
prescribing of systemic antibiotics due to treatment with
fusafungine has been reported in France [15, 16], and conse-
quently an increase in prescribing of systemic antibiotics after
withdrawal of fusafungine may have been expected.
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The most common other N&Ts in fusafungine-prescribing
practices during the study period included mometasone
(21.6%), xylometazoline (14.2%), xylometazoline in combi-
nation with dexpanthenol (10.1%) and multisubstance prepa-
rations (9.7%). These substances may carry their own risks,
for example xylometazoline could cause sympathomimetic
adverse reactions [17–20], and mometasone could cause ad-
renal suppression if significant systemic absorption occurs
when used in high doses over long periods of time [21–23].
Long-term use of nasal decongestants such as xylometazoline
is also associated with a risk of development of rhinitis
medicamentosa [24]. Hence, it is unknown to what extent
the discontinuation of fusafungine and subsequent change in
health care professional behaviour with increased prescribing
of other N&Ts has actually resulted in an improved overall
net-benefit risk balance for patients.
Although the findings are reassuring, our study suggests
that it is important to follow up on the consequences of regu-
latory interventions leading to the withdrawal of medicinal
products from the market and to ascertain the extent
to which substitution by alternative treatments occur,
particularly in cases where alternative treatment options
may themselves confer other risks. The effects of other
measures of drug restrictions, not limited to regulatory
actions, could also be studied using the same methods.
In this regard, a recent systematic review of studies
measuring the impact of regulatory interventions found
that examining unintended consequences of regulatory
decisions, such as substitutions and spill-over effects,
was infrequently performed after implementation of reg-
ulatory actions [25].
This study has some potential limitations. Firstly, the
interrupted time series regression approach only examines
temporal associations which may be influenced by other
factors if occurring during the same time. However, the
absence of an effect within the control practices (non-
fusafungine prescribing) provides further evidence that
the observed effects are indeed related to the withdrawal
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Fig. 1 a–d Quarterly prevalence of treatment prescribing for
consultations with an upper respiratory airways disease (URAD) in gen-
eral practitioner (GP) and ear, nose and throat practices (ENT) in
Germany. a Fusafungine-prescribing GP practices (top left). bGP control
practices not prescribing fusafungine (top right). c Fusafungine-
prescribing ENT practices (bottom left). d ENT control practices not
prescribing fusafungine (bottom right). Horizontal axis, quarterly time
periods between 29 May 2013 and 28 May 2017 starting from quarter 1
(3 years before the withdrawal of fusafungine) to quarter 16 (1 year after
the withdrawal of fusafungine), Vertical axis, percent of consultation days
for a selected diagnosis that concerned the specified treatment pathway.
The dark grey bar indicates the last quarter when fusafungine could still
be prescribed. Treatment pathways: None, no treatment; NT, treatment
with other nasal and throat preparations (not containing fusafungine and
tyrothricin) alone; Tyrothricin, treatment with tyrothricin but no treatment
with systemic antibiotics or fusafungine; Fusafungine, treatment with
fusafungine but no treatment with systemic antibiotics, andAB, treatment
with systemic antibiotics. URAD: acute pharyngitis (ICD code J02.9),
acute laryngitis (ICD code J04.0), acute laryngopharyngitis (ICD code
J06.0) or upper airways infection (ICD code J06.9). Own calculations,
based on IMS® Disease Analyzer Germany
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of fusafungine. Not all studies of the impact of regulatory
interventions have used such robust methods for compar-
ison [25].
Over the counter use of fusafungine as well as any in
hospital prescribing of fusafungine were not captured in
our study, which may limit the generalizability of our
findings. We also selected exposed and unexposed prac-
tices to demonstrate the impact of the fusafungine with-
drawal, and hence not all GP and ENT practices were
included in our study. Furthermore, we only examined
trends in prescribing for the most common consultations
for URAD, the main indication for fusafungine prescrib-
ing, although trends for overall prescribing in practices
with the highest levels of fusafungine prescribing (at
least 5% of all patients; 2 GP practices and 4 ENT
practices) were also similar (data not shown).
In conclusion, the European Medicines Agency regulatory
intervention leading to a withdrawal of fusafungine in the EU
did not lead to substitute prescribing of systemic antibiotics
whereas it did lead to a switch towards higher prescribing of
other N&T products in Germany. In light of concerns about
excessive use of antibiotics that may lead to antibiotic resis-
tance, these results are re-assuring. They also highlight the
need to consider the impact of medicine withdrawals, and
other regulatory interventions, on substitution to other treat-
ments to avoid potential unintended consequences.
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